Literature DB >> 32178547

Challenges and Countermeasures of Integrative Cancer Therapy in the Epidemic of COVID-19.

Geliang Yang1, Huiqing Zhang2, Yufei Yang3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32178547      PMCID: PMC7079301          DOI: 10.1177/1534735420912811

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


× No keyword cloud information.
In December 2019, a novel coronavirus named COVID-19 outbroke in Wuhan, Hubei province, and began spreading rapidly with more than 80 000 cases confirmed and 3000 deaths in China. Italy, Iran, Korea, Japan, the United States, and other countries have reported nearly 60 000 cases. Most COVID-19 patients initially suffered from fever, cough, fatigue, and shortness of breath, while other symptoms included muscle pain, headache, chest pain, and diarrhea, similar to the symptoms observed after chemotherapy, targeted and immune therapy.[1] In addition, cancer itself along with its treatment makes cancer patients more susceptible to pneumonias, due to weakened immune response to respiratory bacteria and virus. Thus, the epidemic spread of COVID-19 has posed great challenges to the clinical practice of oncologists, especially for integrative cancer therapy. According to the latest study revealing the correlation between COVID-19 and cancer, 18 (1%) of 1590 COVID-19 cases had a history of cancer, which was higher than the incidence of cancer (0.29%) in the overall Chinese population; meanwhile, cancer patients were found to have a higher risk of severe events than patients without cancer.[2] We appeal to clinical oncologists to learn the diagnosis of COVID-19 well, and cancer patients should be adequately screened for their epidemiological history, especially for the travel to Wuhan and surrounding areas or other communities with medical records, and respiratory and constitutional symptoms. Generally speaking, anti-COVID-19 therapy should be prior to or combined with other therapy, including anticancer treatment. Integrative cancer therapies such as acupuncture and massage involve close contact with cancer patients, and are widely used to relieve and control a variety of symptoms in cancer patients. We suggest that integrative cancer therapies involving close contact with cancer patients should be rigidly considered or forbidden in endemic areas, and stronger personal protection provisions should be made for patients with cancer and integrative cancer therapists. In high epidemic areas, members of the public are encouraged to reduce going out; thus, Tai Chi and Qi Gong, as integrative therapies, might be very suitable indoor exercises to strengthen the constitution. To our best knowledge, there is still neither a vaccine nor specific antiviral drugs to fight the COVID-19 infection, and current treatments mainly depend on therapy for symptoms. In comparison, one integrative therapy, Chinese herbal medicine (CHM), is widely used in the treatment of COVID-19, and was shown to be quite effective in preliminary clinical practice. China’s National Health Commission issued a Diagnosis and Treatment Protocol for COVID-19, providing a systemic treatment with CHM.[3] Thus, cancer patients diagnosed with mild or medium COVID-19 should be encouraged to receive CHM therapies. In addition, we should strengthen monitoring and give priority to the patients infected with COVID-19 with cancer during CHM treatment, especially the elderly and those with complications. To better understand the treatment of COVID-19 and other severe infectious diseases, more CHM clinical trials should be undertaken as soon as possible, and patients with cancer history should be taken into consideration. We hope that our suggestions could help better deal with challenges of integrative cancer therapy in the epidemic of COVID-19.
  2 in total

1.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

2.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

  2 in total
  12 in total

1.  COVID-19 in Patients with Cancer.

Authors:  Ali Nowroozi; Sepideh Razi; Kamal Kant Sahu; Fabio Grizzi; Jann Arends; Mahsa Keshavarz-Fathi; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Uncertainty upon uncertainty: supportive Care for Cancer and COVID-19.

Authors:  Annie M Young; Fredrick D Ashbury; Lidia Schapira; Florian Scotté; Carla I Ripamonti; Ian N Olver
Journal:  Support Care Cancer       Date:  2020-09       Impact factor: 3.603

3.  Integrative Cancer Therapies: Learning From COVID-19.

Authors:  Keith I Block
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

4.  Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma.

Authors:  Michael Staehler; Dena Battle; Sumanta Kumar Pal; Cristiane Decat Bergerot
Journal:  Eur Urol Focus       Date:  2020-09-11

5.  Integrative Oncology Consultations Delivered via Telehealth in 2020 and In-Person in 2019: Paradigm Shift During the COVID-19 World Pandemic.

Authors:  Santhosshi Narayanan; Gabriel Lopez; Catherine Powers-James; Bryan M Fellman; Aditi Chunduru; Yisheng Li; Eduardo Bruera; Lorenzo Cohen
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

6.  Basic Characteristics, Status, and Challenges of Integrative Oncology in China.

Authors:  Geliang Yang; Huiqing Zhang; Yun Xu; Aiguang Zhao; Peng Shu; Wei Wang; Haibo Zhang; Tingting Wang; Yufei Yang
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

7.  Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".

Authors:  Ayman Abdelmaksoud; Mohamad Goldust; Michelangelo Vestita
Journal:  Dermatol Ther       Date:  2020-04-16       Impact factor: 2.851

8.  Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence.

Authors:  Elissar Moujaess; Hampig Raphael Kourie; Marwan Ghosn
Journal:  Crit Rev Oncol Hematol       Date:  2020-04-22       Impact factor: 6.625

9.  COVID-19 and financial toxicity in patients with renal cell carcinoma.

Authors:  Michael D Staehler; Dena J Battle; Cristiane D Bergerot; Sumanta Kumar Pal; David F Penson
Journal:  World J Urol       Date:  2020-10-22       Impact factor: 4.226

10.  Cancer patient management strategy in a Cancer Center of Zhejiang, China during the COVID-19 pandemic.

Authors:  Songxiao Xu; Xiangdong Cheng; Zhiwen Pan; Qian Song; Yihong Wang; Juan Xiong; Yongyi Chen; Fan Fan; Jing Zhu; Wanying Wu; Xueying Deng; Yanpin Yu; Xiaohong Xu; Wenhu Chen; Tao Zhu; Yang Yu; Kaizhong Liu; Guoliang Shao; Ming Chen; Enyan Yu
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.